|
Vebreltinib
Vebreltinib (also known as bozitinib) is a pharmaceutical drug used for the treatment of cancer. Vebreltinib selectively binds to c-Met, preventing its phosphorylation and thereby disrupting c-Met signal transduction pathways. In China, it is approved for the treatment of non-small-cell lung cancer Non-small-cell lung cancer (NSCLC), or non-small-cell lung carcinoma, is any type of epithelial lung cancer other than small-cell lung cancer (SCLC). NSCLC accounts for about 85% of all lung cancers. As a class, NSCLCs are relatively insensitiv ... (NSCLC) with MET exon 14 skipping mutations. References Antineoplastic and immunomodulating drugs Kinase inhibitors Indazoles Cyclopropyl compounds Pyrazoles Fluoroarenes {{antineoplastic-drug-stub ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
C-Met
Hepatocyte growth factor receptor (HGF receptor) is a protein that in humans is encoded by the ''MET'' gene. The protein possesses tyrosine kinase activity. The primary single chain precursor protein is post-translationally cleaved to produce the alpha and beta subunits, which are disulfide linked to form the mature receptor. HGF receptor is a single pass tyrosine kinase receptor essential for embryonic development, organogenesis and wound healing. Hepatocyte growth factor/Scatter Factor (HGF/SF) and its splicing isoform (NK1, NK2) are the only known ligands of the HGF receptor. MET is normally expressed by cells of epithelial origin, while expression of HGF/SF is restricted to cells of mesenchymal origin. When HGF/SF binds its cognate receptor MET it induces its dimerization through a not yet completely understood mechanism leading to its activation. Sometimes MET is misunderstood as of an abbreviation of Mesenchymal-Epithelial Transition. It is incorrect. The three letters ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |